Congenital Dyserythropoietic Anemia Type I (CDA I): A Patient Guide

Congenital Dyserythropoietic Anemia Type I (CDA I) is an ultra-rare, inherited condition that changes how your body produces oxygen-carrying red blood cells. In a healthy system, the bone marrow acts as a factory, maturing red blood cells until they are ready to carry oxygen throughout the body. In CDA I, this factory is disrupted by a process called ineffective erythropoiesis. Due to mutations in specific genes—most commonly CDAN1 or CDIN1—the developing red blood cells fail to mature correctly, and many abnormal or immature cells die before they ever reach the bloodstream ^[1][2].

This disruption often presents as a combination of chronic anemia, fatigue, and jaundice, which is a yellowing of the eyes and skin caused by the rapid breakdown of these abnormal cells ^[3]. While some people are diagnosed shortly after birth with severe symptoms, others may not be identified until adulthood, having lived for years with unexplained tiredness or mild anemia. Because CDA I is so rare, receiving a definitive diagnosis supported by genetic testing is a landmark moment that allows you to move away from general “anemia” treatments and toward a plan designed specifically for this condition ^[4].

Living with CDA I requires a proactive, lifelong approach to monitoring. One of the most important aspects of care is the management of iron. Even if you or your child never requires a blood transfusion, the body’s response to the anemia can cause it to absorb and store too much iron, which can eventually affect the liver, heart, and hormone-producing glands ^[5]. Do not take over-the-counter iron supplements to treat anemia unless your doctor has confirmed true iron deficiency. Regular surveillance using specialized imaging, such as an MRI T2*, allows your medical team to track iron levels accurately and intervene with treatments like iron chelation before complications arise ^[6].

Fortunately, specialized treatments are available that can change the course of the disease for some patients. Interferon-alpha has emerged as a key therapy for CDA I, helping to improve the way red blood cells mature and often significantly increasing hemoglobin levels ^[7]. While the journey with an ultra-rare disease can feel isolating, understanding the underlying biology of your condition and working with a dedicated care team can help you manage symptoms effectively and maintain a full, active life ^[4].